

FOR YOUR ADULT PATIENTS
WITH HR+/HER2- mBC¹

YOU MEASURE
SUCCESS BY
MEANINGFUL
MOMENTS.

SO DOES
IBRANCE.

IBRANCE[®]
palbociclib
Made for mBC



Not actual patients. Image only for representation purpose only

IBRANCE[®] (Palbociclib)
Prescribing Information:
[https://labeling.pfizer.com/
ShowLabeling.aspx?id=17707](https://labeling.pfizer.com/ShowLabeling.aspx?id=17707)



For more than 8 years, IBRANCE has helped protect moments like these.²⁻⁵ Supported by broad clinical and real-world experience, strong efficacy and favorable tolerability,^{1,4,6-35} IBRANCE helps your patients get the most out of every day^{4,5,36,37}

HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; mBC = metastatic breast cancer.

References:

1. IBRANCE[®] (palbociclib) Malaysian Prescribing Information dated 04 August 2020. 2. Beaver JA, et al. Clin Cancer Res. 2015;21(21):4760-4766. 3. George MA, et al. Front Oncol. 2021;11:693104. 4. Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729. 5. Rugo HS, et al. Ann Oncol. 2018;29:888-894. 6. Cristofanilli M, et al. Clin Cancer Res. 2022;28(16):3433-3442. 7. Xu B, et al. Eur J Cancer. 2022;175:234-245. 8. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1935. 9. Gelmon K, et al. Breast. 2021;59:321-326. 10. Rugo HS, et al. Eur J Cancer. 2018;101:123-133. 11. Turner NC, et al. Ann Oncol. 2018;29(3):669-680. 12. Cristofanilli F, et al. Lancet Oncol. 2016;17(4):425-439. 13. Harbeck N, et al. Future Oncol. 2021;17(16):2917-2122. 14. Goyal RK, et al. Cancer. 2023 Feb 9. Epub ahead of print. 15. Richardson D, et al. Breast Cancer Res Treat. 2021;187(1):113-124. 16. De Michele A, et al. Breast Cancer Res. 2021;23:37. 17. Rugo HS, et al. NPJ Breast Cancer. 2022;8(1):114. 18. Taylor-Stokes G, et al. Breast. 2019;43:22-27. 19. Waller J, et al. J Glob Oncol. 2019;5:JGO1800239. 20. Mycock K, et al. SABCS. 2019; Poster P3-11-25. 21. Mycock K, et al. Curr Oncol. 2021;28:679-688. 22. Mycock K, et al. Cancer Treat Res Commun. 2022;32:100573. Epub 6 May 2022. 23. Mycock K, et al. Clin Ther. 2022;44(12):1588-1601. 24. Kraus AL, et al. Clin Pharmacol Ther. 2022;111(1):302-309. 25. Rugo HS, et al. SABCS 2022; Abstract P3-01-15. 26. De Laurentis M, et al. SABCS. 2019; Poster P3-11-25. 27. Caletk P. ASCO 2021; Oral presentation 1012. 28. Tripathy D, et al. ESMO 2022; Poster 231P. 29. Karuturi MS, et al. ESMO BC 2022; Poster 190P. 30. Blum J, et al. SABCS 2021; Abstract P1-18-29. 31. Finn R, et al. ASCO 2022; Oral presentation. 32. Finn R, et al. Oncologist. 2021;26:e749-e755. 33. Dieras V, et al. Oncologist. 2019;24(12):1514-1525. 34. Verma S, et al. Oncologist. 2016;21(10):1165-1175. 35. Harbeck N, et al. Ann Oncol. 2016;27(6):1047-1054. 36. Rocque G, et al. ESMO 2022; Poster 266P. 37. Karuturi M, et al. SABCS 2021; Poster P1-18-25.

For Healthcare Professionals Only



Pfizer Malaysia Sdn. Bhd. 197801003134 (40131-T)
Level 10 & 11, Wisma Avenir, Tower 2, Avenue 5,
Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur.
Tel: 603-2281 6000 Fax: 603-2281 6388

PP-IBR-MYS-0482-22MAY2023



LORVIQUA
LORLATINIB

INDICATIONS

- LORVIQUA as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor¹
- LORVIQUA as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after:
 - Alectinib[®] ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
 - Crizotinib and at least one other ALK TKI.

Full Prescribing Information
LORVIQUA[®] (lorlatinib) Prescribing Information:
<https://labeling.pfizer.com/ShowLabeling.aspx?id=17716>
Accessed June 23, 2023

Scan Here for full prescribing information



LORVIQUA (lorlatinib)
is indicated for the

FIRST LINE

treatment for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).¹



Pfizer (Malaysia) Sdn Bhd 197801003134 (40131-T)
Level 10 & 11, Wisma Avenir, Tower 2, Avenue 5, Bangsar South,
No. 8, Jalan Kerinchi, 59200 Kuala Lumpur.
Tel: +(603) 2281 6000 Fax: +(603) 2281 6388 www.pfizer.com.my

Reference: 1. LORVIQUA[®] (lorlatinib) Malaysian Prescribing Information dated 13 September 2022.
For Healthcare Professionals Only
PP-LOR-MYS-0016-25AUG2022